AbbVie: Rinvoq, a monoclonal antibody against JAK enzyme, has superior efficacy in patients with atopic dermatitis compared to Dupixent
20% of patients treated with Rinvoq achieved 90% or greater reduction on the Eczema Area and Severity Index (EASI) and attained a 0 or 1 grade on the Worst Pruritis Numerical Rating Scale (WP-NRS) compared to 9% of patients treated with Dupixent. The rate of...